Lipid Testing After Myocardial Infarction at the Montreal Heart Institute
Launched by MONTREAL HEART INSTITUTE · Apr 24, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial at the Montreal Heart Institute is studying how reliable certain cholesterol tests are for patients who have had a heart attack (myocardial infarction). Specifically, the researchers want to see if measurements of LDL (bad cholesterol), non-HDL cholesterol, and apoB levels stay consistent during the hospital stay. This is important because doctors often make treatment decisions based on these tests taken when a patient is admitted for a heart attack.
To participate, you need to be an adult (18 years or older) who is hospitalized for a heart attack, and willing to give your consent. If you join the study, you will have a blood test for cholesterol done on your first day in the hospital and again on the second day. Researchers will then compare these results to see if they change over time, including about 4 to 6 weeks after you leave the hospital. This study is currently not recruiting participants yet, but it could play a crucial role in understanding how to better treat patients after a heart attack.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patients ≥18 years old
- • Hospitalized at the Cardiac Care Unit for Myocardial Infarction (either NSTEMI or STEMI)
- • Lipid panel performed on day 0 of admission
- • Willing to provide informed consent
- Exclusion Criteria:
- • None
About Montreal Heart Institute
The Montreal Heart Institute (MHI) is a leading academic research center dedicated to advancing the field of cardiology through innovative clinical trials and groundbreaking medical research. Renowned for its commitment to improving patient care, MHI integrates clinical practice with cutting-edge research, fostering collaboration among healthcare professionals, scientists, and industry partners. The institute focuses on a wide range of cardiovascular conditions, aiming to develop and evaluate new therapies and interventions that enhance outcomes for patients with heart disease. With a strong emphasis on ethical standards and patient safety, the Montreal Heart Institute is at the forefront of cardiovascular research, contributing significantly to the global advancement of heart health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Montreal, Quebec, Canada
Montréal, Quebec, Canada
Patients applied
Trial Officials
Guillaume Marquis-Gravel, MD, MSc
Principal Investigator
Montreal Heart Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported